Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Mol Cancer Res. 2017 Feb 27;15(7):905–914. doi: 10.1158/1541-7786.MCR-16-0369

Figure 6. USP18 immunostaining is augmented in human lung adenocarcinomas with activating KRAS mutations.

Figure 6

Representative immunostaining of human lung adenocarcinomas with (A) low versus high USP18 expression. (B) Representative USP18 expression profiles are shown for KRAS wild-type versus mutant lung cancers relative to adjacent normal lung tissues. All magnifications are 40X. (C) USP18 immunostaining in normal (n = 76) versus malignant (n = 81) lung was compared and significantly higher (P < 0.001) USP18 levels were detected in the malignant lung. (D) USP18 immunostaining was compared in KRAS wild-type (n = 42) versus mutant (n = 39) lung cancer cases and significantly (P < 0.05) higher USP18 expression was evident in cases where mutant KRAS was detected.